GlaxoSmithKline has become the first pharmaceutical company to take Adimab’s antibody discovery platform in-house as part of a deal that provides the company with a broad, non-exclusive licence to use the technology to discover and optimise antibody therapeutics of all formats. Adimab has also expanded its 2011 collaboration with Biogen Idec with a technology transfer and licensing deal focused on Biogen’s targeted therapeutic areas. The deals represent a change in strategy for Adimab, which has to date entered into research collaborations covering one or a small number of targets.